These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36864254)

  • 1. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
    van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
    Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of KRAS
    Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
    ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
    Yoshino T; Van Cutsem E; Li J; Shen L; Kim TW; Sriuranpong V; Xuereb L; Aubel P; Fougeray R; Cattan V; Amellal N; Ohtsu A; Mayer RJ
    ESMO Open; 2022 Jun; 7(3):100511. PubMed ID: 35688062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.
    Doleschal B; Taghizadeh H; Lentner T; Riedl JM; Granitzer J; Morariu D; Decker J; Aichberger KJ; Webersinke G; Kirchweger P; Petzer A; Rumpold H
    ESMO Open; 2023 Dec; 8(6):102064. PubMed ID: 37977001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
    Basso M; Signorelli C; Calegari MA; Lucchetti J; Zurlo IV; Dell'Aquila E; Arrivi G; Zoratto F; Santamaria F; Saltarelli R; Trovato G; Caira G; Angotti L; Schirripa M; Anghelone A; Schietroma F; Chilelli MG; Salvatore L; Pozzo C; Tortora G
    Target Oncol; 2024 May; 19(3):371-382. PubMed ID: 38613732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
    Hamers PAH; Vink GR; Elferink MAG; Stellato RK; Dijksterhuis WPM; Punt CJA; Koopman M; May AM;
    Clin Colorectal Cancer; 2022 Jun; 21(2):154-166. PubMed ID: 35474007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
    Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
    Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
    Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS
    Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
    Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
    Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Elez E; Cruz FM; Wyrwicz L; Stroyakovskiy D; Pápai Z; Poureau PG; Liposits G; Cremolini C; Bondarenko I; Modest DP; Benhadji KA; Amellal N; Leger C; Vidot L; Tabernero J;
    N Engl J Med; 2023 May; 388(18):1657-1667. PubMed ID: 37133585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
    Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J
    ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
    Shiroyama M; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Shimada Y; Esaki T; Makiyama A; Moriwaki T
    Sci Rep; 2023 Oct; 13(1):17931. PubMed ID: 37863951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer.
    Hara S; Sakai D; Ikemura K; Shintani T; Yamamoto T; Satoh T; Okuda M
    Anticancer Res; 2024 Mar; 44(3):1219-1226. PubMed ID: 38423630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
    Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
    Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.
    Victorino APOS; Meton F; Mardegan L; Festa J; Piranda DN; Araujo KB
    J Geriatr Oncol; 2023 May; 14(4):101477. PubMed ID: 36990929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
    Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
    Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H
    PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
    Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K
    Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.